Pfizer to buy Array Biopharma for $10.64 billion

Pfizer to buy Array Biopharma for $10.64 billion

Pfizer said on Monday it would acquire Array Biopharma for $10.64 billion in cash, giving it access to the target’s approved drugs for skin cancer and the targeted cancer medicines in its pipeline. The offer of $48 per Array share represents a premium of about 62 per cent to the stock’s close on Friday.

KCooper
KCooper
Miles O'Brien
Miles O'Brien 1 year

The FTC and FDA need to stop the big pharmas from building their monopolies. There is no benefit to the public.

Top in Business
Get the App